Abstract:Abstract Overly restrictive eligibility criteria for clinical trials may limit the generalizability of the trial results to their target real-world patient populations. We developed a novel machine learning approach using large collections of real-world data (RWD) to better inform clinical trial eligibility criteria design. We extracted patients’ clinical events from electronic health records (EHRs), which include demographics, diagnoses, and drugs, and assumed certain compositions of these clinical events within an individual’s EHRs can determine the subphenotypes—homogeneous clusters of patients, where patients within each subgroup share similar clinical characteristics. We introduced an outcome-guided probabilistic model to identify those subphenotypes, such that the patients within the same subgroup not only share similar clinical characteristics but also at similar risk levels of encountering severe adverse events (SAEs). We evaluated our algorithm on two previously conducted clinical trials with EHRs from the OneFlorida+ Clinical Research Consortium. Our model can clearly identify the patient subgroups who are more likely to suffer or not suffer from SAEs as subphenotypes in a transparent and interpretable way. Our approach identified a set of clinical topics and derived novel patient representations based on them. Each clinical topic represents a certain clinical event composition pattern learned from the patient EHRs. Tested on both trials, patient subgroup (#SAE=0) and patient subgroup (#SAE>0) can be well-separated by k-means clustering using the inferred topics. The inferred topics characterized as likely to align with the patient subgroup (#SAE>0) revealed meaningful combinations of clinical features and can provide data-driven recommendations for refining the exclusion criteria of clinical trials. The proposed supervised topic modeling approach can infer the clinical topics from the subphenotypes with or without SAEs. The potential rules for describing the patient subgroups with SAEs can be further derived to inform the design of clinical trial eligibility criteria.

Considerations on Subgroup Analysis in Design and Analysis of Multi-Regional Clinical Trials

Practical Recommendations for Regional Consistency Evaluation in Multi-Regional Clinical Trials with Different Endpoints

Research report on guidance for the multi-regional clinical trials

Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials

Regional efficacy evaluation in multi‐regional clinical trials using a discounting factor weighted Z test

Inference of treatment effect and its regional modifiers using restricted mean survival time in multi-regional clinical trials

Application of estimand framework to the design and analysis of multi-regional clinical trials

Multi-regional clinical trials and global drug development

Some Recent Advances on Statistical Approaches for Planning Multi-regional Clinical Trials

A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity

Subgroup identification in clinical trials: an overview of available methods and their implementations with R

RegionSizeR- A Novel App for Regional Sample Size Planning in MRCTs

Influence Diagnostics of a Region of Interest in Multi-regional Clinical Trials

Analysis of influencing factors on observed regional difference in treatment effects in clinical trial

Machine learning enabled subgroup analysis with real-world data to inform clinical trial eligibility criteria design

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

The necessary conduct: Exploratory multiregional clinical trials in East Asia

Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials

Qualitative Consistency of Treatment Effects in Multiregional Clinical Trials

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

Simultaneous Global Drug Development and Multiregional Clinical Trials (MRCT): 5 Years After Implementation of ICH E17 Guidelines